Bauersachs R, Berkowitz S D, Brenner B, Buller H R, Decousus H, Gallus A S, Lensing A W, Misselwitz F, Prins M H, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson B L, Piovella F, Schellong S. EINSTEIN Investigators: Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med 2010 Dec; 363 (26):2499-2510
Decousus H, Tapson V F, Bergmann J F, Chong B H, Froehlich J B, Kakkar A K, Merli G J, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer F A, Spyropoulos A C, Turpie A G, Zotz R B, Fitzgerald G, Anderson F A, For The Improve (International Medical Prevention Registry On Venous Thromboembolism) Investigators.
Factors at Admission Associated With Bleeding Risk in Medical Patients:Findings From IMPROVE. Chest. 2011 Jan;139(1):69-79
Warkentin TE, Davidson BL, Buller HR, Gallus A, Gent M, Lensing AW, Piovella F, Prins MH, Segers AE, Kelton JG, Prevalence and Risk of Pre-existing Heparin-induced Thrombocytopenia Antibodies in Patients with Acute Venous Thromboembolism, Chest 2011 Aug; 140 (2):366-373;
Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; for the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Investigators
Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for Venous Thromboembolism, Chest. 2011 Sep;140(3):706-14
Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE (Piovella F); Cassiopea Investigators Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan; 379(9811):123-9
Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (Piovella F); EINSTEIN–PE Investigators, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med 2012 Apr; 366(14):1287-97
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, (Piovella F); AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism., N Engl J Med. 2013;368 (8):699-708
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (Piovella F); AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369 (9):799-808
Hokusai-VTE Investigators Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (Piovella F, Picchi C, Iosub DI) Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, N Engl J Med. 2013; 369 (15): 1406-1415
Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, (Piovella F); on behalf of the ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014 Jul 8;130(2):138-46 Piovella F, Iosub DI New anticoagulants in the management of venous thromboembolism in women Thromb Res 2015 135 (Suppl.1) S5-S7 Piovella F, Iosub DI: Acute pulmonary embolism: risk assessment, risk stratification and treatment options. Clin Respir J. 2016;10(5):545-54.
Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE: European Union-28: An annualised cost-of-illness model for venous thromboembolism. Thromb Haemost. 2016;115(4):800-8.
Piovella F, Iosub DI: Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism. Thromb Res. 2017;152:87-92.
Piovella F, Iosub DI: Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?.Intern Emerg Med. 2018 Oct;13(7):993-5.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE (Piovella F) on behalf of the MARINER Steering, Executive Committees and Investigators: Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
